| Dr Kenneth H Golden, MD | |
|
39 Simon St Ste 2a, Nashua, NH 03060-3046 | |
| (603) 888-4347 | |
| (603) 521-8571 |
| Full Name | Dr Kenneth H Golden |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 43 Years |
| Location | 39 Simon St Ste 2a, Nashua, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356408801 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 51577 (Massachusetts) | Secondary |
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 12102 (New Hampshire) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Merrimack Valley Counseling Association | 1557325172 | 7 |
News Archive
Aclaris Therapeutics, Inc. today announced positive results from a Phase 2 clinical trial of the Company's lead drug, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing seborrheic keratoses (SK), one of the most common types of skin tumors.
Oncolytics Biotech Inc. today announced that an abstract covering preclinical research with reovirus (REOLYSIN) is available on the European CanCer Organisation (ECCO). The research is scheduled to be presented at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics being held in Berlin, Germany from November 16th - 19th 2010.
Research at the University of Adelaide has shed new light onto the possible causes of sudden infant death syndrome (SIDS), which could help to prevent future loss of children's lives.
An important advance in understanding the structure of phage viruses, which infect and destroy bacteria, has been made by a team of scientists from Oxford and Finland, which could help develop new strategies to combat bacterial infections.
Noting "French researchers have identified 14 adults" who appear to have been functionally cured of HIV after beginning treatment "within a couple of months of infection" and continuing treatment "for one to seven and a half years" before stopping, a New York Times editorial writes, "The researchers estimate that as many as 15 percent of adults who start treatment early and continue for at least a year may then be able to stop their drug regimen and live healthily without the drugs."
› Verified 8 days ago
| Entity Name | Merrimack Valley Counseling Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508905472 PECOS PAC ID: 1557325172 Enrollment ID: O20041115000169 |
News Archive
Aclaris Therapeutics, Inc. today announced positive results from a Phase 2 clinical trial of the Company's lead drug, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing seborrheic keratoses (SK), one of the most common types of skin tumors.
Oncolytics Biotech Inc. today announced that an abstract covering preclinical research with reovirus (REOLYSIN) is available on the European CanCer Organisation (ECCO). The research is scheduled to be presented at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics being held in Berlin, Germany from November 16th - 19th 2010.
Research at the University of Adelaide has shed new light onto the possible causes of sudden infant death syndrome (SIDS), which could help to prevent future loss of children's lives.
An important advance in understanding the structure of phage viruses, which infect and destroy bacteria, has been made by a team of scientists from Oxford and Finland, which could help develop new strategies to combat bacterial infections.
Noting "French researchers have identified 14 adults" who appear to have been functionally cured of HIV after beginning treatment "within a couple of months of infection" and continuing treatment "for one to seven and a half years" before stopping, a New York Times editorial writes, "The researchers estimate that as many as 15 percent of adults who start treatment early and continue for at least a year may then be able to stop their drug regimen and live healthily without the drugs."
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kenneth H Golden, MD 39 Simon St. Suite 2a, Merrimack Valley Counseling Assoc., Nashua, NH 03060-3043 Ph: (603) 888-4347 | Dr Kenneth H Golden, MD 39 Simon St Ste 2a, Nashua, NH 03060-3046 Ph: (603) 888-4347 |
News Archive
Aclaris Therapeutics, Inc. today announced positive results from a Phase 2 clinical trial of the Company's lead drug, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing seborrheic keratoses (SK), one of the most common types of skin tumors.
Oncolytics Biotech Inc. today announced that an abstract covering preclinical research with reovirus (REOLYSIN) is available on the European CanCer Organisation (ECCO). The research is scheduled to be presented at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics being held in Berlin, Germany from November 16th - 19th 2010.
Research at the University of Adelaide has shed new light onto the possible causes of sudden infant death syndrome (SIDS), which could help to prevent future loss of children's lives.
An important advance in understanding the structure of phage viruses, which infect and destroy bacteria, has been made by a team of scientists from Oxford and Finland, which could help develop new strategies to combat bacterial infections.
Noting "French researchers have identified 14 adults" who appear to have been functionally cured of HIV after beginning treatment "within a couple of months of infection" and continuing treatment "for one to seven and a half years" before stopping, a New York Times editorial writes, "The researchers estimate that as many as 15 percent of adults who start treatment early and continue for at least a year may then be able to stop their drug regimen and live healthily without the drugs."
› Verified 8 days ago
Santharam Yadati, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 436 Amherst St Ste 101, Nashua, NH 03063 Phone: 603-627-4764 Fax: 603-577-9595 | |
Pamela N Olsson, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 7 Prospect St., Nashua, NH 03060 Phone: 603-889-6147 Fax: 603-883-1568 | |
Dr. Kimberly K Whitesell, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 7 Prospect St., Nashua, NH 03060 Phone: 603-889-6147 Fax: 603-883-1568 | |
Dr. Cynthia Brown Stevens, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 7h Black Oak Dr, Nashua, NH 03062 Phone: 703-509-2753 | |
Bettina Peyton, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 22 Prospect Street, Home Health & Hospice, Nashua, NH 03060 Phone: 603-882-2941 | |
Dr. Robert S Dealy, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 7 Prospect St., Nashua, NH 03060 Phone: 603-889-6147 Fax: 603-883-1568 | |
Andreja Packard, MD PHD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 17 Prospect St, Nashua, NH 03060 Phone: 603-577-5300 Fax: 603-577-5305 |